Skip to content
Triangle logo TriangleGet started
← Melanoma

HEALTH PROFESSIONAL · SOURCE READING

Interleukin-2 (IL-2)

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Immunotherapy

The FDA approved IL-2 in 1998 because of durable complete response rates in a minority of patients (6%–7%) with previously treated metastatic melanoma in eight phase I and II studies. Phase III trials have not been conducted to compare high-dose IL-2 with other treatments or to determine the impact on OS.

Preserved source evidence · Not medical advice